A Novel Role for Raloxifene Nanomicelles in Management of Castrate Resistant Prostate Cancer

Of patients with castrate resistant prostate cancer (CRPC), less than 25–33% survive more than five years. Recent studies have implicated estrogen, acting either alone or synergistically with androgens in the development of castrate resistant prostate cancer. Several in vitro and in vivo studies, as...

Descripción completa

Detalles Bibliográficos
Autores principales: Taurin, Sebastien, Nehoff, Hayley, van Aswegen, Thalita, Rosengren, Rhonda J., Greish, Khaled
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932713/
https://www.ncbi.nlm.nih.gov/pubmed/24689036
http://dx.doi.org/10.1155/2014/323594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932713/
https://www.ncbi.nlm.nih.gov/pubmed/24689036
http://dx.doi.org/10.1155/2014/323594

Ejemplares similares